186 related articles for article (PubMed ID: 17612055)
1. Inflammation in Parkinson's disease: causative or epiphenomenal?
Hald A; Van Beek J; Lotharius J
Subcell Biochem; 2007; 42():249-79. PubMed ID: 17612055
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald A; Lotharius J
Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
[TBL] [Abstract][Full Text] [Related]
3. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
4. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.
Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Izal-Azcárate A; Belzunegui S; Marcilla I; López B; Luquin MR
J Neuropathol Exp Neurol; 2009 Sep; 68(9):977-84. PubMed ID: 19680145
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
[TBL] [Abstract][Full Text] [Related]
6. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
7. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Hunter RL; Dragicevic N; Seifert K; Choi DY; Liu M; Kim HC; Cass WA; Sullivan PG; Bing G
J Neurochem; 2007 Mar; 100(5):1375-86. PubMed ID: 17254027
[TBL] [Abstract][Full Text] [Related]
8. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?
Rogers J; Mastroeni D; Leonard B; Joyce J; Grover A
Int Rev Neurobiol; 2007; 82():235-46. PubMed ID: 17678964
[TBL] [Abstract][Full Text] [Related]
9. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
McGeer PL; Schwab C; Parent A; Doudet D
Ann Neurol; 2003 Nov; 54(5):599-604. PubMed ID: 14595649
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
Watanabe Y; Himeda T; Araki T
Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
[TBL] [Abstract][Full Text] [Related]
11. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.
Reynolds AD; Banerjee R; Liu J; Gendelman HE; Mosley RL
J Leukoc Biol; 2007 Nov; 82(5):1083-94. PubMed ID: 17675560
[TBL] [Abstract][Full Text] [Related]
14. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic role of glial cells in Parkinson's disease.
Teismann P; Tieu K; Cohen O; Choi DK; Wu DC; Marks D; Vila M; Jackson-Lewis V; Przedborski S
Mov Disord; 2003 Feb; 18(2):121-9. PubMed ID: 12539204
[TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Kreisler A; Gelé P; Wiart JF; Lhermitte M; Destée A; Bordet R
Brain Res; 2007 Mar; 1135(1):77-84. PubMed ID: 17196944
[TBL] [Abstract][Full Text] [Related]
17. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse.
Pierri M; Vaudano E; Sager T; Englund U
Neuropharmacology; 2005 Mar; 48(4):517-24. PubMed ID: 15755479
[TBL] [Abstract][Full Text] [Related]
18. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
19. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.
Marchetti B; Serra PA; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Cioni S; Gennuso F; Rocchitta G; Desole MS; Mazzarino MC; Miele E; Morale MC
Ann N Y Acad Sci; 2005 Dec; 1057():296-318. PubMed ID: 16399902
[TBL] [Abstract][Full Text] [Related]
20. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
Kalkonde YV; Morgan WW; Sigala J; Maffi SK; Condello C; Kuziel W; Ahuja SS; Ahuja SK
Brain Res; 2007 Jan; 1128(1):1-11. PubMed ID: 17126305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
